ARTICLE | Finance
Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
March 24, 2014 7:00 AM UTC
AB Science S.A. (Euronext:AB) fell €1.61 (11%) to €12.67 on Friday after EMA's CHMP again recommended against conditional approval of masitinib for second-line treatment of gastrointestinal stromal tumors. AB Science was appealing a November CHMP negative opinion.
The committee said it still had "major concerns" about masitinib's benefits and said there were "outstanding problems related to quality control during its manufacture."...